Compare Air Products & Chemicals, Inc. (APD) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs BioNTech SE - ADR — how do they compare? Air Products & Chemicals, Inc. trades at $306 (market cap $68.88B), while BioNTech SE - ADR trades at $92.57 (market cap $23.31B). The key difference: Air Products & Chemicals, Inc. is far larger — about 3× BioNTech SE - ADR's market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| APD | BNTX | |
|---|---|---|
Market Cap | $68.88B | $23.31B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $119.34 |
52-Week Low | $230.42 | $83.89 |
Enterprise Value | $86.06B | $6.60B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $308.18, up 1.56% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS of $3.47 exceeding expectations. Recent positive developments include a major semiconductor supply agreement in Taiwan and raised guidance, though profitability metrics show weakness with negative net income margin and ROE. Analyst consensus remains strongly bullish with a $346 price target representing 12% upside potential.
APD presents a growth opportunity driven by strategic contracts and consistent earnings beats, but faces fundamental challenges with negative profitability and elevated debt levels. The stock's technical strength and institutional support provide near-term momentum, though investors should weigh the disconnect between valuation multiples and current financial performance against the company's long-term growth prospects in industrial gases.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
